EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection

Yuanyuan Qiao, Jesse W Wotring iD, Charles J Zhang, Xia Jiang, Lanbo Xiao, Andy Watt, Danielle Gattis, Eli Scandalis, Susan Freier, Yang Zheng, Carla D Pretto, Stephanie J Ellison und 4 weitere

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0281281 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Yuanyuan Qiao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, United States of America. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Howard Hughes Medical Institute, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although the COVID-19 pandemic began over three years ago, the virus responsible for the disease, SARS-CoV-2, continues to infect people across the globe. As such, there remains a critical need for development of novel therapeutics against SARS-CoV-2. One technology that has remained relatively unexplored in COVID-19 is the use of antisense oligonucleotides (ASOs)—short single-stranded nucleic acids that bind to target RNA transcripts to modulate their expression. In this study, ASOs targeted against the SARS-CoV-2 genome and host entry factors, ACE2 and TMPRSS2 , were designed and tested for their ability to inhibit cellular infection by SARS-CoV-2. Using our previously developed SARS-CoV-2 bioassay platform, we screened 180 total ASOs targeting various regions of the SARS-CoV-2 genome and validated several ASOs that potently blocked SARS-CoV-2 infection in vitro . Notably, select ASOs retained activity against both the WA1 and B.1.1.7 (commonly known as alpha) variants. Screening of ACE2 and TMPRSS2 ASOs showed that targeting of ACE2 also potently prevented infection by the WA1 and B.1.1.7 SARS-CoV-2 viruses in the tested cell lines. Combined with the demonstrated success of ASOs in other disease indications, these results support further research into the development of ASOs targeting SARS-CoV-2 and host entry factors as potential COVID-19 therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansAngiotensin-Converting Enzyme 2Oligonucleotides, AntisensePandemicsPeptidyl-Dipeptidase AVirus Internalization

Substanzen

Angiotensin-Converting Enzyme 2Oligonucleotides, AntisensePeptidyl-Dipeptidase A

Autor:innen und Institutionen

  • Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, United States of America.
  • Department of Pathology, University of Michigan, Ann Arbor, MI, United States of America.
  • Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States of America.
  • Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI, United States of America.
  • Ionis Pharmaceuticals, Carlsbad, CA, United States of America.
  • Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States of America.

ORCID-Profile: Jesse W Wotring, Arul M Chinnaiyan

Förderung

  • NIDDK NIH HHS
  • Howard Hughes Medical Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • American Foundation for Pharmaceutical Education

Zitieren

APA

Qiao, Y., Wotring, J. W., Zhang, C. J., Jiang, X., Xiao, L., Watt, A., Gattis, D., Scandalis, E., Freier, S., Zheng, Y., Pretto, C. D., Ellison, S. J., Swayze, E. E., Guo, S., Sexton, J. Z., & Chinnaiyan, A. M. (2023). Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection. PLOS ONE. https://doi.org/10.1371/journal.pone.0281281

Vancouver

Qiao Y, Wotring JW, Zhang CJ, Jiang X, Xiao L, Watt A, et al. Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection. PLOS ONE. 2023. doi:10.1371/journal.pone.0281281

BibTeX
@article{Qiao2023,
  author = {Qiao, Yuanyuan and Wotring, Jesse W and Zhang, Charles J and Jiang, Xia and Xiao, Lanbo and Watt, Andy and Gattis, Danielle and Scandalis, Eli and Freier, Susan and Zheng, Yang and Pretto, Carla D and Ellison, Stephanie J and Swayze, Eric E and Guo, Shuling and Sexton, Jonathan Z and Chinnaiyan, Arul M},
  title = {Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0281281}
}
Kostenlos starten →